HDAC3 and osteosarcoma: These findings are quite interesting, as CBX4 targeting the Runx2 promoter has two opposite effects via recruiting HDAC3 and GCN5 to alter the status of H3K27Ac to impair and enhance Runx2, which in turn inhibits and promotes CRC and osteosarcoma metastases, respectively.